The EMPEROR-Preserved study looked at the effects of empagliflozin in participants with heart failure with a preserved ejection fraction (HFpEF). This is when the lower left part of the heart (left ventricle) squeezes normally or near normally but does not fill with enough blood between heartbeats. Therefore, not enough blood is pumped around the body. For this study, HFpEF was defined as a condition in which more than 40% of blood in the left ventricle was pumped around the body. This Plain Language Summary of Publication article from Future Cardiology summarises a study called EMPEROR-Preserved, the study specifically looked at the effects of a medication called empagliflozin in participants with a type of heart failure called preserved ejection fraction (HFpEF). In people HFpEF the lower part of the heart (left ventricle) can squeeze normally, however does not fill with enough blood between heartbeats.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes’, and was published in Circulation, 

Visit AHA Journals using the link to read the original article.